AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 12 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Scientists have determined oligodeoxynucleotides containing CpG motifs (CpG-ODNs) can act as a tumor vaccine, preventing the formation of new tumors in rats cured of previously established glioma.
CpG-ODNs cause tumor rejection on two fronts, taking advantage of both innate immunity and specific immune response, based on evidence gathered by G. Auf and associates working for the French research consortium INSERM. Several investigations are presently underway in order to establish the possibility of using these CpG-ODNS as tumor vaccines.
Auf and INSERM colleagues used several types of rodents, including normal and macrophage depleted Fisher rats, and nude and SCID mice to perform their analyses of CpG-ODNs and immune system response.
Intermittent administration of CpG-ODNs to rats with normal macrophage levels up to 19 days after they were given subcutaneous inoculations of 9 L glioma cells resulted in significant reductions in tumor volume. In contrast, tumors continued to grow in control rats treated with normal saline. The effect of CpG-ODN therapy on tumor inhibition was seen in over a third of the treated rats, Auf and coworkers reported (Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen, Clinical Cancer Research, November 2001;7(11):3540-3543).
Tumor-specific long-term protective immunity was also evident, as cured ...